PortugalPortugal

Iberian support for new flu vaccine

12.07.2009

Madrid –The Spanish Ministry of Health is investing in future biotech treatments. In July, it signed a EUR60m contract over a recombinantly manufactured flu vaccine developed by Rockville-based Novavax.
In Phase II trials, the company is currently testing a vaccine based on virus-like particles without viral RNA. Novavax hopes to develop pandemic and seasonal flu vaccines, and plans to seek regulatory approval by 2012 in Europe.
The company will develop the vaccines with Spanish drugmaker ROVI Pharmaceuticals. Under separate agreements that are being negotiated by both companies, ROVI will receive exclusive licenses to Novavax’s portable VLP vaccine technology to commercialise flu vaccines in Spain and Portugal, and non-exclusive licenses in Europe, Latin America and Africa. Furthermore, under a stock purchase agreement, ROVI has committed to make a US$3m equity investment in Novavax at $2.74 per share,
To acccomplish the deal, ROVI and the Spanish authorities will establish a joint non-profit foundation to be initially funded with a a25m line of credit from the Spanish government. The funds will support Phase III clinical development and other studies necessary to achieve marketing authorisation of the VLP influenza vaccines.
Additional clinical development funds will be contributed by ROVI if required. In addition, the State of Andalucía will support the drugmaker in building a new VLP vaccine plant in Granada, and bring it on-line in 2012 at a cost of EUR20m. The plant is expected to have enough manufacturing capacity to service Spain and other parts of Europe, Latin America, and Africa.

PortugalPortugal

19.08.2008

Lisbon – The international contract research organisation Chiltern sees potential for growth in Portugal. In May, it opened a new office in Lisbon that will be managed by Ricardo Diaz. Over the last two years, numbers of clinical...

PortugalPortugal

19.03.2008

Porto – 164 farmers planted a total of 4,199 hectares of genetically modified maize in Portugal in 2007, according to a report issued by the Portuguese Ministry of Agriculture. That represents a 330% increase compared to 2006,...

PortugalPortugal

22.11.2007

Cantanhede – Biogen Idec (Cambridge, US) and the Portuguese biopark Biocant in the Coimbra region have signed a socalled ‘Sponsored Research Agreement’ worth an undisclosed amount. Under the terms of the agreement, researchers...

Portugal, SpainPortugal

11.07.2007

Oeiras/Navarra – Portuguese antibody and genomics specialist Biotecnol SA and the Spanish university spin-off Digna Biotech will develop a process for manufacturing cardiotrophin-1 (CT-1) for the treatment of ischemic-reperfusion...

PortugalPortugal

11.07.2007

Porto – In September 2005, the Portuguese government established a decree law (No. 160/2005) on the co-existence between genetically modified organisms (GMO), conventional and organic crops. In short, it recommends a minimum...

PortugalPortugal

11.07.2007

Almada – transADVANcis Lda, a consultancy firm for nanotechnology and life sciences executives, has launched a website called www.nanogolive.com. With the new portal, on which anyone from the nanotechnology and life science...

PortugalPortugal

16.05.2007

Porto – Two Portuguese biotech companies have won the national idea contest for bio-entrepreneurs (Concurso de Ideias Bioempreendedor 2006), organized every year by the Portuguese Association of Bioindustries (APBio) and the...

PortugalPortugal

16.03.2007

Port Salvo – Biotrend S.A., developers of high-value compounds based in Lisbon, has closed a second investment round with the public venture capital outfit PME Investimientos, ending with a total investment exceeding 1 million...

PortugalPortugal

16.03.2007

Porto Salvo – Alfama, developers of small molecule drugs, has opened a laboratory in Boston, Massachusetts, in order to achieve US presence. The company will carry out research on the effects of self-developed molecules on...

Italy, PortugalPortugal

16.09.2006

Milan/Sintra – The Italian pharmaceutical company Recordati S.p.A agreed in July to acquire Jaba Farmacêutica (Sintra, Portugal) and all other pharmaceutical businesses belonging to the Grupo Jaba in Portugal. The purchase price...

Displaying results 11 to 20 out of 37

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-portugal/browse/1/article/iberian-support-for-new-flu-vaccine.html

Product of the week

Products

Events

All Events

Current issue

All issues